# AI/ML Clinical Deployment Roadmap

**Status:** 🟡 INFRASTRUCTURE READY | MODELS NOT READY FOR CLINICAL USE

**Date:** April 19, 2026

---

## Executive Summary

MedSync AI/ML infrastructure is production-ready for **testing and UX validation only**. The current models are placeholders and rule-based fallbacks. **They must not be used to guide clinical decisions** until validated on real clinical data.

### Key Points

- ✅ **Infrastructure**: APIs, authentication, audit logging, governance — all production-ready
- ❌ **Models**: Placeholder scores based on synthetic data, not validated on real patients
- ⚠️ **Patient Safety Risk**: Doctors using placeholder scores for triage/referral decisions without clinical training
- 📋 **What's Needed**: Clinical validation study + model training + regulatory review

---

## What "Production-Ready" Means (Clarification)

### Infrastructure Production-Ready ✅

"Production-ready" for infrastructure means:
- Endpoints are stable and tested
- Authentication/authorization working correctly
- Audit logging captures all predictions
- Multi-tenant hospital scoping enforced
- Error handling is robust
- Performance is acceptable
- Scalability is designed for multi-hospital network

**Can be deployed to:** Development, staging, test servers for UX validation

### NOT Production-Ready for Clinical Use ❌

"Production-ready for clinical use" would require:
- Models trained on real patient cohorts
- Clinical validation against patient outcomes
- Sensitivity/specificity documented
- Bias assessment completed
- Regulatory approval obtained
- Clinician protocols established
- Incident reporting mechanism ready

**Current state does NOT have any of these.**

---

## Current Model Status: Why Placeholders Are Not Safe

### What Placeholder Models Are

```
Placeholder Model = Synthetic Data Patterns
├─ Training: Fictional distributions based on medical knowledge
├─ Not trained on: Actual patient outcomes from your hospitals
├─ Validation: None against real clinical populations
├─ Risk: Predictions may not match real clinical patterns
└─ Appropriate for: UX testing, architecture validation only
```

### Example: Why This Matters

**Scenario:** Placeholder model predicts 80% heart disease risk for a patient
- ✅ Acceptable if showing in UX mockup to clinicians: "This is what risk would look like"
- ❌ NOT acceptable if doctor uses this to decide cardiology referral
- ❌ Patient is referred to cardiology based on synthetic data distribution
- ❌ If true risk is 20%, patient gets unnecessary expensive workup
- ❌ Clinical resources wasted + patient anxiety + potential harm

### Risk If Deployed Without Training

| Risk | Impact | Severity |
|------|--------|----------|
| Over-triage (false positives) | Unnecessary referrals, wasted resources, patient anxiety | High |
| Under-triage (false negatives) | Missed emergencies, delayed care, patient harm | CRITICAL |
| Biased triage (by gender/age/ethnicity) | Discrimination, liability, patient safety | High |
| Unvalidated scores | Doctors lose trust in system, stop using it | High |
| Liability | Hospital liable if adverse outcome linked to placeholder model | Critical |

---

## Roadmap to Clinical Deployment

### Phase 1: Data Collection & Preparation (Months 1-3)

**Objective:** Gather clinical data to train and validate models

**Tasks:**

1. **Patient Cohort Selection**
   - [ ] Identify patient populations for model training
   - [ ] For risk prediction: Patients with documented 5-year outcomes
   - [ ] For diagnosis: Patients with confirmed diagnoses (from lab/imaging/pathology)
   - [ ] For triage: ED patients with documented outcomes
   - Target: Min 1,000 patients per condition (bigger is better)

2. **Data Extraction**
   - [ ] Extract from existing hospital EMR systems
   - [ ] Map to MedSync data model (vitals, labs, medications, diagnoses)
   - [ ] Identify outcomes (mortality, readmission, complications, etc.)
   - [ ] Remove personally identifiable info (de-identify)

3. **Data Quality Assurance**
   - [ ] Check for missing values (imputation strategy)
   - [ ] Validate data ranges (outlier detection)
   - [ ] Ensure temporal ordering (causes before effects)
   - [ ] Clinician review of unusual patterns

4. **Ethics & Compliance**
   - [ ] Institutional Review Board (IRB) approval
   - [ ] Patient consent (or waiver if retrospective)
   - [ ] Data privacy compliance (GDPR/Ghana healthcare regs)
   - [ ] Data use agreement with hospitals

### Phase 2: Model Development & Validation (Months 3-6)

**Objective:** Train models on real data and validate against clinical outcomes

**Tasks:**

1. **Model Training**
   - [ ] Split data: 70% training, 15% validation, 15% test
   - [ ] Train XGBoost models (risk predictor, diagnosis classifier, triage)
   - [ ] Hyperparameter tuning on validation set
   - [ ] Cross-validation (5-fold or 10-fold)
   - [ ] Model performance: AUC >= 0.75, Sensitivity >= 0.85

2. **Clinical Validation**
   - [ ] Test on hold-out test set (unseen data)
   - [ ] Document metrics per condition:
     - Sensitivity (catch positives): What % of true cases identified?
     - Specificity (exclude negatives): What % of true negatives identified?
     - AUC: Overall discrimination ability (0.5=random, 1.0=perfect)
     - Calibration: Are predicted probabilities accurate?
   - [ ] Compare against standard scores (NEWS2, qSOFA)
   - [ ] Clinical team review: "Do these results make sense?"

3. **Bias Assessment**
   - [ ] Fairness audit: Performance across demographics
     - Age groups (18-40, 40-65, 65+)
     - Gender (M/F)
     - Ethnicity (if available)
   - [ ] If disparity found: Retrain with fairness constraints
   - [ ] Goal: Parity of performance across demographics

4. **Prospective Validation (Optional but Recommended)**
   - [ ] Deploy model to limited set of hospitals
   - [ ] Monitor real predictions vs actual outcomes
   - [ ] Collect feedback from clinicians
   - [ ] Iterate if needed

### Phase 3: Regulatory & Governance (Months 6-9)

**Objective:** Obtain regulatory approval and establish clinical governance

**Tasks:**

1. **Regulatory Review**
   - [ ] Submit models to Ghana Health Service (or equivalent)
   - [ ] Provide: Clinical validation report, bias assessment, risk analysis
   - [ ] Receive: Classification (low/medium/high risk AI)
   - [ ] Obtain: Approval to deploy

2. **Clinical Governance**
   - [ ] Clinician protocol: When to use AI predictions?
   - [ ] Override procedure: How to override AI recommendation?
   - [ ] Decision-making: AI is tool for clinician, not replacement
   - [ ] Training: Educate clinicians on model capabilities & limitations

3. **Incident Reporting**
   - [ ] Adverse event reporting: What to do if patient harmed?
   - [ ] Feedback mechanism: Clinicians report prediction errors
   - [ ] Escalation: How to investigate + improve model

4. **Documentation**
   - [ ] Model card: What does model do? Limitations? Bias assessment?
   - [ ] Risk mitigation: How are risks addressed?
   - [ ] Liability: Who is responsible if model fails?

### Phase 4: Deployment & Monitoring (Months 9+)

**Objective:** Deploy to production clinical workflows with monitoring

**Tasks:**

1. **Staged Rollout**
   - [ ] Deploy to pilot hospital (with close monitoring)
   - [ ] Monitor for 2-4 weeks: Are predictions accurate in real use?
   - [ ] Collect clinician feedback
   - [ ] Expand to other hospitals if all good

2. **Post-Market Monitoring**
   - [ ] Track model performance over time
   - [ ] Alert if performance degrades (data drift)
   - [ ] Regular audits: Is model still fair across demographics?
   - [ ] Feedback loop: Collect new data for periodic retraining

3. **Continuous Improvement**
   - [ ] Retrain model annually (or when new data available)
   - [ ] Add new features (patient feedback, new clinical data)
   - [ ] Update models as medical knowledge evolves

---

## Recommended Timeline

| Phase | Duration | Key Deliverable |
|-------|----------|-----------------|
| Phase 1: Data Prep | 3 months | Training cohort of 1,000+ patients |
| Phase 2: Model Dev | 3 months | Validated models with AUC >= 0.75 |
| Phase 3: Regulatory | 3 months | Regulatory approval |
| Phase 4: Deploy | Ongoing | Production models + monitoring |
| **TOTAL** | **9+ months** | **Clinically validated deployment** |

---

## Current Guidance: DO NOT USE PLACEHOLDER MODELS CLINICALLY

### What You CAN Do Now

✅ **Allowed (Development/Testing):**
- Test UX/UI with placeholder models
- Verify endpoint functionality
- Demonstrate capability to stakeholders
- Show examples to potential clinical team
- Validate infrastructure (auth, logging, multi-tenancy)

### What You CANNOT Do Now

❌ **Prohibited (Clinical Use):**
- Deploy to production clinical workflows
- Allow doctors to use predictions for patient triage/referral
- Use risk scores to guide clinical decisions
- Report AI predictions in patient records as clinical advice
- Make clinical protocols based on placeholder scores

### Risk If Violated

- Patient harm (over/under-triage, delayed care)
- Liability (hospital responsible if patient harmed)
- Loss of clinician trust ("These scores are wrong")
- Regulatory action (health authority shutdown)
- Reputational damage

---

## Summary

| Aspect | Current | Required | Timeline |
|--------|---------|----------|----------|
| **Infrastructure** | ✅ Ready | ✅ Already met | Now |
| **Models** | 🟡 Placeholder | ❌ Real data needed | 9+ months |
| **Clinical Validation** | ❌ None | ✅ Required | 6 months (Phase 2) |
| **Regulatory Approval** | ❌ None | ✅ Required | 3 months (Phase 3) |
| **Clinical Deployment** | ❌ NOT READY | ✅ Required | After Phase 3 |

**Current Status: Infrastructure production-ready; Models development-stage.**

**Recommendation: Deploy infrastructure now for testing; Do NOT use predictions clinically until models trained and validated.**
